Cingulate Inc.
Business
Cingulate Inc. is a biopharmaceutical company developing proprietary Precision Timed Release (PTR) drug delivery platform technology to create once-daily formulations of existing drugs for conditions with burdensome dosing regimens. The company's lead candidate CTx-1301 (dexmethylphenidate) targets ADHD across children, adolescents, and adults; CTx-1302 (dextroamphetamine) targets ADHD; and CTx-2103 (buspirone) targets anxiety. Cingulate has established partnerships with Indegene and IQVIA for marketing, sales, and distribution services, and contracts manufacturing to Bend Biosciences (Societal CDMO).
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 10 | 9 | 15 | 9 | 8 | |
| General and administrative | 10 | 6 | 7 | 9 | 12 | |
| Operating loss | −20 | −16 | −23 | −18 | −21 | |
| Issuance cost and change in fair value of derivative | −1 | −1 | — | — | — | |
| Interest and other income (expense), net | −1 | 99,236 | — | — | — | |
| Loss before income taxes | −22 | −17 | −24 | −18 | −21 | |
| Income tax benefit (expense) | — | — | — | — | — | |
| Net loss and comprehensive loss | −22 | −17 | −24 | −18 | −21 | |
| Net loss per share of common stock, basic | −4.44 | −10.86 | −311.99 | −29.35 | −2.79 | |
| Net loss per share of common stock, diluted | −4.44 | −10.86 | −311.99 | −29.35 | — | |
| Weighted average number of shares used in computing net loss per share of common stock, basic | 5 | 2 | 75,435 | 602,340 | 7 | |
| Weighted average number of shares used in computing net loss per share of common stock, diluted | 5 | 2 | 75,435 | 602,340 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 11 | 12 | 52,416 | 5 | 16 | |
| Miscellaneous receivables | 8,013 | 26,325 | 14,622 | 234,432 | 690,248 | |
| Prepaid expenses and other current assets | 1 | 423,157 | 511,556 | 2 | 2 | |
| Total current assets | 12 | 13 | 578,594 | 8 | 19 | |
| Property and equipment, net | 2 | 2 | 3 | 3 | 3 | |
| Operating lease right-of-use assets | 1 | 99,011 | 366,877 | 630,618 | 858,600 | |
| Total assets | 15 | 15 | 3 | 11 | 23 | |
| Accounts payable | 2 | 1 | 5 | 762,357 | 264,687 | |
| Accrued expenses | 2 | 1 | 2 | 894,635 | 601,300 | |
| Notes payable, current | 6 | 3 | 3 | 5 | — | |
| Finance lease liability, current | — | 4,430 | 17,057 | 16,053 | 15,096 | |
| Operating lease liability, current | 238,864 | 130,662 | 358,085 | 339,755 | 295,595 | |
| Total current liabilities | 10 | 5 | 10 | 7 | 1 | |
| Note payable | 1 | 2 | — | — | — | |
| Operating lease liability, net of current | 1 | — | 130,663 | 488,748 | 828,503 | |
| Total long-term liabilities | 2 | 2 | 135,099 | 510,235 | 866,037 | |
| Total liabilities | 13 | 7 | 10 | 8 | 2 | |
| Common Stock, $0.0001 par value; 240,000,000 shares authorized and 7,250,299 and 3,402,306 shares issued and outstanding as of December 31, 2025 and 2024 | 725 | 340 | 10 | 61 | 1,131 | |
| Preferred Stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding as of December 31, 2025 and 2024 | — | — | — | — | — | |
| Additional Paid-in-Capital | 135 | 117 | 86 | 73 | 73 | |
| Accumulated deficit | −132 | −110 | −93 | −69 | −52 | |
| Total stockholders equity | 3 | 7 | −7 | 4 | 21 | |
| Total liabilities and stockholders equity | 15 | 15 | 3 | 11 | 23 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 540,894 | 653,090 | 582,918 | 394,011 | 708,317 | |
| Stock-based compensation | 2 | 995,484 | 812,670 | 800,796 | 43,835 | |
| Accretion of discount on note payable | 326,006 | — | — | — | — | |
| Amortization of debt issue costs | 26,525 | — | — | — | — | |
| Loss on debt extinguishment | 805,951 | — | — | — | — | |
| Miscellaneous receivables | 18,312 | −11,703 | 219,810 | 455,816 | −538,476 | |
| Prepaid expenses and other current assets | −623,705 | 88,399 | 2 | −580,591 | −1 | |
| Operating lease right-of-use assets | −1 | 267,886 | 263,741 | 227,982 | 100,124 | |
| Trade accounts payable and accrued expenses | 1 | −5 | 5 | 791,005 | −1 | |
| Current portion of operating lease liability | 108,202 | −227,424 | 18,330 | 44,160 | 61,427 | |
| Long-term portion of operating lease liability | 1 | −130,663 | −358,085 | −339,755 | −228,938 | |
| Net cash used in operating activities | −17 | −18 | −15 | −16 | −10 | |
| Purchase of property and equipment | −162,138 | −211,800 | −224,096 | −153,420 | −814,736 | |
| Net cash used in investing activities | −162,138 | −211,800 | −224,096 | −152,652 | −814,736 | |
| Proceeds from the issuance of common stock and pre-funded common stock purchase warrants, net of fees | 10 | 26 | 7 | — | 20 | |
| Proceeds from notes payable | 6 | 5 | 3 | 5 | — | |
| Principal payments on finance lease obligations | −4,430 | −17,063 | −16,047 | −15,090 | −436,259 | |
| Net cash provided by financing activities | 16 | 31 | 10 | 5 | 27 | |
| Net increase (decrease) in cash and cash equivalents | −1 | 12 | −5 | −11 | 15 | |
| Property and equipment accrued but not paid at end of year | — | 31,160 | 186,960 | — | 279,730 | |
| Interest paid | 19,895 | 6,288 | 19,421 | 19,000 | 114,725 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cingulate Inc.'s CIK number?
Cingulate Inc.'s SEC CIK number is 0001862150 (1862150). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cingulate Inc.'s SEC filings?
All of Cingulate Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Cingulate Inc. last report earnings?
Cingulate Inc. (CINGW) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022881). This is Cingulate Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Cingulate Inc.'s most recent earnings 8-K?
Cingulate Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001493152-26-022881. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Cingulate Inc.'s latest earnings 8-K →
Look up any company's CIK number →